来氟米特联合匹伐他汀钙片治疗伴血脂异常CKD1-2期慢性肾小球肾炎患者的疗效及机制分析  

Efficacy and mechanism analysis of leflunomide combined with pitavastatin calcium tablets in patients with CKD1-2 chronic glomerulonephritis with dyslipidemia

作　　者：张磊 潘茜 ZHANG Lei;PAN Qian(Department of Kidney disease,Zhangjiagang Hospital of Traditional Chinese Medicine,Zhangjiagang 215600,China;不详)

机构地区：[1]张家港市中医医院肾病科 [2]张家港市中医医院心内科,江苏张家港215600

出　　处：《中国处方药》2022年第4期79-81,共3页Journal of China Prescription Drug

摘　　要：目的探讨与分析来氟米特联合匹伐他汀钙片治疗伴血脂异常CKD1-2期慢性肾小球肾炎患者的疗效及机制。方法选择2018年1月~2021年4月诊治的伴血脂异常CKD1-2期慢性肾小球肾炎患者128例作为研究对象,根据随机信封抽签原则把患者分为联合组与对照组各64例。对照组给予来氟米特治疗,联合组在对照组治疗的基础上给予匹伐他汀治疗,两组都治疗观察8周。结果治疗后联合组的总有效率为98.4%,高于对照组的89.1%(P<0.05)。两组治疗后的血肌酐与尿素氮水平低于治疗前,联合组低于对照组(P<0.05)。联合组治疗后的甘油三酯(triglyceride,TG)、总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(low-density lipoprotein-cholesterol,LDL-C)含量低于治疗前(P<0.05),高密度脂蛋白胆固醇(high-density lipoprotein-cholesterol,HDL-C)含量高于治疗前(P<0.05),对照组治疗前后血脂水平变化对比差异无统计学意义(P>0.05)。两组治疗后的血清超敏C反应蛋白(high sensitive C-reactive protein,hs-CRP)与肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)水平低于治疗前(P<0.05),联合组低于对照组(P<0.05)。结论来氟米特联合匹伐他汀钙片在治疗伴血脂异常CKD1-2期慢性肾小球肾炎患者的应用能促进改善肾功能与血脂紊乱水平,抑制炎症因子的表达,从而提高总体治疗效果。Objective To investigate and analyze the efficacy and mechanism of leflunomide combined with pivastatin calcium tablet in the treatment of chronic glomerulonephritis of CKD stage 1-2 with dyslipidemia.Methods From January 2018 to April 2021,128 cases of patients with CKD1-2 chronic glomerulonephritis with dyslipidemia were selected as the research objects.The patients were equally divided into the combination group and the control group accorded to the principle of random envelope drawing.The control group were given leflunomide treatment,and the combination group were given pitavastatin treatment on the basis of the control group's treatment.Both groups were treated and observed for 8 weeks.Results After treatment,the total effective rate of the combination group were 98.4%,which were higher than 89.1%of the control group(P<0.05).The serum creatinine and urea nitrogen levels after treatment in the two groups were lower than before treatment(P<0.05),and the combination group were lower than the control group(P<0.05).The levels of triglyceride(TG),total cholesterol(TC),and low-density lipoprotein-cholesterol(LDL-C)after treatment in the combination group were lower than before treatment(P<0.05).The levels of high-density lipoprotein-cholesterol(HDL-C)were higher than before treatment(P<0.05).There were no significant difference in the changes of blood lipid levels compared between before and after treatment in the control group(P>0.05).The serum levels of high sensitive C-reactive protein(hs-CRP)and tumor necrosis factor-α(TNF-α)after treatment in the two groups were lower than before treatment(P<0.05),and the combination group were lower than the control group(P<0.05).Conclusion The application of leflunomide combined with pivastatin calcium tablet in the treatment of patients with chronic glomerulonephritis with dyslipidemia stage 1-2 can promote the improvement of renal function and dyslipidemia level,inhibit the expression of inflammatory factors,and thus improve the overall therapeutic effect.

关 键 词：来氟米特 匹伐他汀 血脂 肾小球肾炎 炎症因子 超敏C反应蛋白 

分 类 号：R692.31[医药卫生—泌尿科学]